Demand forecast draws a 1087-to-1 competition ratio as institutions flock to 라이브스코어 바카라사이트-powered br라이브스코어 바카라사이트n disease solutions
[by Sung, Jae Jun] Neurophet, a company specializing in artificial intelligence (AI) solutions for the diagnosis and treatment of brain diseases, announced on July 14 that it has set its initial public offering (IPO) price at KRW 14,000 (approximately USD 10.1), marking the upper limit of the proposed pricing range.
According to the company, a total of 2,444 Korean and international institutions participated in the demand forecast for institutional investors conducted from July 4 to 10, resulting in a competition rate of 1,087.6 to 1. Notably, 100% of participating institutions submitted bids exceeding the upper limit of the proposed public offering price range. 라이브스코어 바카라사이트 is scheduled to proceed with general public subscription on July 15 and 16 and aims to be listed on the KOSDAQ market on July 25.
Mirae Asset Securities, the lead underwriter for 라이브스코어 바카라사이트’s listing, stated, “The strong results in the demand forecast were likely driven by 라이브스코어 바카라사이트’s technological competitiveness in the medical AI sector, its potential for future revenue growth, and market expectations for collaboration with global pharmaceutical firms.”
“We have confirmed strong market interest in AI-based solutions for the diagnosis and treatment of brain diseases,” said Jake Junkil Been, co-CEO of 라이브스코어 바카라사이트. “With the growing adoption of Alzheimer’s disease treatments, demand for brain imaging analysis is also increasing. In response, we plan to further expand the clinical application of our solutions and pursue global collaborative research initiatives.”